Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health
June 28, 2024 18:43 ET
|
Pacific Software Inc.
Pacific Software Inc. expands into memory health with SuppleMEM AD™ and A.L.Z. Defense™. USA and Mexico distribution is planned for Q3 2024.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
June 10, 2024 09:00 ET
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
June 03, 2024 09:00 ET
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
Longeveron® to Attend BIO International Convention 2024
May 28, 2024 08:05 ET
|
Longeveron
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
Pacific Software Inc. Acquires Scientifically Tested Medical Food Cocktail Focused on Memory Health
May 24, 2024 09:00 ET
|
Pacific Software Inc.
Pacific Software Inc. expands into brain health, acquiring proven SuppleMEM AD™ and A.L.Z. Defense™, backed by NIH research for strategic growth and profit
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
May 21, 2024 08:00 ET
|
Bionano Genomics
Optical genome mapping was used in three publications to successfully assess genome integrity in stem cells, CAR-T cells, and iPSCs.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Announces Board of Directors Planned Transitions
May 10, 2024 16:05 ET
|
Longeveron
Longeveron announces planned transitions on its Board of Directors.
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 08, 2024 09:00 ET
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration